Total Clarity Wealth Management Inc. Invests $386,000 in TransMedics Group, Inc. $TMDX

Total Clarity Wealth Management Inc. acquired a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,879 shares of the company’s stock, valued at approximately $386,000.

Other large investors also recently modified their holdings of the company. OneDigital Investment Advisors LLC grew its position in shares of TransMedics Group by 52.6% during the 1st quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company’s stock worth $403,000 after buying an additional 2,065 shares during the period. Principal Financial Group Inc. grew its position in shares of TransMedics Group by 2.8% during the 1st quarter. Principal Financial Group Inc. now owns 198,427 shares of the company’s stock worth $13,350,000 after buying an additional 5,480 shares during the period. Vontobel Holding Ltd. acquired a new stake in shares of TransMedics Group during the 1st quarter worth approximately $291,000. New York State Teachers Retirement System grew its position in shares of TransMedics Group by 183.2% during the 1st quarter. New York State Teachers Retirement System now owns 21,949 shares of the company’s stock worth $1,477,000 after buying an additional 14,200 shares during the period. Finally, Peregrine Capital Management LLC grew its stake in TransMedics Group by 3.4% in the first quarter. Peregrine Capital Management LLC now owns 68,390 shares of the company’s stock valued at $4,601,000 after acquiring an additional 2,250 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Wall Street Zen cut TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, August 30th. Morgan Stanley raised their price objective on TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Oppenheimer raised their price objective on TransMedics Group from $130.00 to $150.00 and gave the company an “outperform” rating in a research note on Tuesday, June 17th. Finally, Zacks Research cut TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Seven research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and an average price target of $127.18.

TransMedics Group Stock Up 4.1%

TMDX stock opened at $111.71 on Tuesday. The stock’s 50 day moving average is $116.88 and its 200-day moving average is $112.70. The firm has a market capitalization of $3.81 billion, a PE ratio of 57.88 and a beta of 2.08. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $145.50. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.44. The business had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.TransMedics Group’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same period last year, the company posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Sell-side analysts expect that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.